Point72 Asset Management L.P. purchased a new position in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,863,435 shares of the biopharmaceutical company’s stock, valued at approximately $21,989,000. Point72 Asset Management L.P. owned about 4.00% of Sucampo Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Krensavage Asset Management LLC raised its stake in shares of Sucampo Pharmaceuticals by 0.6% during the second quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after purchasing an additional 16,570 shares during the last quarter. LSV Asset Management raised its stake in shares of Sucampo Pharmaceuticals by 1.9% during the second quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 44,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Sucampo Pharmaceuticals by 13.0% during the second quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after purchasing an additional 189,561 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Sucampo Pharmaceuticals by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after purchasing an additional 15,528 shares during the last quarter. Finally, Royce & Associates LP raised its stake in shares of Sucampo Pharmaceuticals by 9.7% during the third quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock worth $13,826,000 after purchasing an additional 103,808 shares during the last quarter. Institutional investors and hedge funds own 65.31% of the company’s stock.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.13% of the company’s stock.

Several equities research analysts have recently commented on the company. BidaskClub upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. B. Riley upped their price target on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Mizuho cut Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $14.00 to $12.00 in a research note on Tuesday, October 3rd. UBS cut their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, October 12th. Finally, Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.60.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at $16.50 on Thursday. The stock has a market capitalization of $766.01, a price-to-earnings ratio of 11.13, a price-to-earnings-growth ratio of 4.84 and a beta of 1.47. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals, Inc. has a 52-week low of $9.30 and a 52-week high of $17.70.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. Sucampo Pharmaceuticals’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.30 earnings per share. equities analysts expect that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/14/1863435-shares-in-sucampo-pharmaceuticals-inc-scmp-acquired-by-point72-asset-management-l-p.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Stock Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related stocks with our FREE daily email newsletter.